Last reviewed: May 16, 2026
Last updated: May 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
A Shedrx review highlights key considerations for GLP-1 users: compounded medication sourcing, transparent pricing models, and how individual metabolic factors influence treatment suitability. Many patients compare multiple platforms before selecting a GLP-1 provider, making informed evaluation essential.
What matters most is understanding your own metabolic context and how different GLP-1 compounds may fit your clinical picture. PlexusDx emphasizes precision wellness through genetic insights and licensed 503A compounding, allowing providers to tailor recommendations based on your specific peptide pathway predispositions.
Compounded vs. Branded GLP-1 Medications: What Patients Should Know
GLP-1 medications exist in two primary forms: branded pharmaceuticals (Ozempic, Wegovy, Mounjaro) manufactured by large pharma, and compounded versions created in licensed 503A pharmacies. Both carry regulatory oversight, but sourcing, cost, and availability differ significantly between these pathways.
Compounded GLP-1 medications offer flexibility and often lower costs, but require prescriptions from licensed providers and careful pharmacy verification. Understanding the difference between 503A compounding (patient-specific, smaller batches) and 503B manufacturing (larger sterile operations) helps patients evaluate safety and quality standards accurately.
Pricing Models and Transparent Cost Structures
GLP-1 platforms vary widely in pricing, from subscription models to à la carte consultations plus medication fees. A Shedrx review typically emphasizes cost clarity—knowing whether genetic testing, provider fees, and shipping are included or additional helps patients budget accurately.
PlexusDx pricing includes compounded semaglutide starting at $149 monthly, tirzepatide from $249 monthly, and genetic testing at $99 as an add-on or $298 standalone. Transparent pricing allows patients to compare total cost of care across multiple providers fairly.
| Service Component |
Typical Cost Range |
What It Includes |
| Compounded Semaglutide (monthly) |
$149 |
Medication only, 4-week supply from 503A pharmacy |
| Compounded Tirzepatide (monthly) |
$249 |
Medication only, 4-week supply from 503A pharmacy |
| Precision Peptide Genetic Test |
$99–$298 |
Predisposition analysis in GLP1R, GIPR, FTO, MC4R pathways; standalone or add-on |
| Provider Consultation |
Included/varies |
Initial intake, dose escalation guidance, safety monitoring |
Genetic Predispositions and Personalized Medication Selection
Individual variation in GLP-1 response partly reflects genetic predispositions in peptide receptor pathways. Variants in GLP1R, GIPR, FTO, and MC4R genes can influence metabolic efficiency, appetite signaling, and medication effectiveness. Genetic testing may provide useful context for provider conversations.
The Precision Peptide Genetic Test reveals predispositions in these four key metabolic pathways, helping providers understand why certain patients respond differently to the same GLP-1 compound. This information may support more tailored dosing, compound selection, or lifestyle integration—though genetics never predicts exact response in isolation.
Safety, Eligibility, and Provider-Led Decision Making
GLP-1 medications are prescription drugs requiring medical evaluation for contraindications, such as personal or family history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease. Any review of GLP-1 providers should confirm they conduct thorough health screening before prescribing.
A qualified provider should discuss your full medical history, current medications, metabolic markers, and treatment goals before recommending a specific compound or dose. Genetic test results should be interpreted within this clinical context—they provide predisposition insights, not medical advice or guarantees of outcome.
How PlexusDx Supports a More Personalized Approach
PlexusDx genetic testing may help provide context about your individual peptide pathway predispositions—specifically GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 variants. This information can support a more informed conversation with your provider about whether compounded semaglutide, tirzepatide, or other GLP-1 options align with your metabolic profile.
The Precision Peptide Genetic Test does not predict exact medication response or guarantee outcome. Instead, it reveals predispositions that may influence how your body processes GLP-1 compounds and manages appetite regulation. Combined with your clinical history, biomarkers, and provider assessment, this knowledge supports personalized decision-making.
Understanding your genetic context alongside transparent pricing, verified 503A pharmacy sourcing, and qualified provider oversight creates a complete picture. PlexusDx integrates these elements to help patients evaluate GLP-1 options with their healthcare team, moving beyond generic marketing toward precision wellness.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How does Shedrx's business model compare to other GLP-1 platforms?
Shedrx operates a telehealth-to-pharmacy model with subscription billing. PlexusDx similarly connects patients to licensed providers and 503A compounding, but emphasizes genetic testing and transparent flat per-compound pricing to support personalized provider conversations rather than algorithmic matching.
What is the difference between 503A compounded and branded GLP-1 medications?
Branded medications (Ozempic, Wegovy) are mass-manufactured by pharmaceutical companies. Compounded versions are prepared in licensed 503A pharmacies per individual prescriptions. Both require provider oversight, but compounding offers cost flexibility and sourcing transparency.
How much do PlexusDx compounded GLP-1 medications cost?
PlexusDx compounded semaglutide ranges from $149 monthly, tirzepatide from $249 monthly. The Precision Peptide Genetic Test is $99 as an add-on or $298 standalone. Pricing includes medication and basic provider support; insurance coverage varies by plan.
Can genetic testing predict how well a GLP-1 medication will work for me?
Genetic testing reveals predispositions in peptide pathways (GLP1R, GIPR, FTO, MC4R), which may provide context for personalized treatment. However, genetics alone does not predict exact medication response—clinical history, biomarkers, and provider assessment are equally important for informed decision-making.
Who should not use GLP-1 medications like those offered through platforms like Shedrx?
GLP-1 is contraindicated in patients with personal or family history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease. Pregnancy, severe kidney disease, and certain medications also require provider evaluation. Always disclose your complete medical history before starting any GLP-1 therapy.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Sesame's GLP-1 Option: What the Program Includes and How It Compares
Agile Telehealth GLP-1: Evaluating Remote Prescribing and Genetic Context